Biohaven Ltd. (BHVN)

Biohaven Ltd.'s stock price has experienced significant volatility and a notable decline in the past six months. In December 2025, the company's experimental depression drug BHV-7000 failed to meet its primary endpoint, leading to a share selloff and discontinuation of psychiatric research for Opakalim. In November 2025, Biohaven announced a proposed public offering of common shares, reported its Third Quarter 2025 financial results, and saw analysts adjust their ratings and price targets. Insider purchases were also reported in November 2025. Biohaven's stock plummeted after the FDA rejected its Vyglxia drug, leading the company to cut R&D spending and prioritize other programs.

As a clinical-stage biopharmaceutical company, Biohaven Ltd. does not currently have commercialized products generating revenue, so traditional product demand seasonality is not a significant factor. The company's financial performance is more influenced by clinical trial milestones, regulatory approvals, and funding activities rather than seasonal product demand.

Biohaven Ltd. is a global clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for neurological, psychiatric, immunological, and oncological diseases. Its neuroscience programs include Kv7 ion channel modulation, TRPM3 antagonism, glutamate modulation, and TYK2/JAK1 inhibition. Immunology programs leverage extracellular protein degradation. Oncology programs develop antibody recruiting, bispecific molecules, and antibody-drug conjugates. The company also has programs in muscle and metabolism, including myostatin inhibition. Biohaven was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Biohaven Ltd. is a global biopharmaceutical company with a primary focus on discovery and development in the United States. The company's headquarters are in New Haven, Connecticut. A significant portion of its shareholders are based in the United States, accounting for approximately 73.0% to 74.04% of the geographical origin of shareholders.

Biohaven Ltd.'s brand reputation has been significantly influenced by its clinical trial outcomes and subsequent analyst reactions. The consensus analyst rating for Biohaven is "Moderate Buy," but the company has faced downgrades from some analysts following setbacks. The failure of the BHV-7000 depression drug in a Phase 2 trial in December 2025 led to a substantial stock price drop and the discontinuation of psychiatric development for the drug. The company's decision to cut R&D spending and prioritize other programs after an FDA rejection in November 2025 also contributed to a negative perception.

Biohaven Ltd. has a mixed ownership structure comprising institutional, retail, and individual investors. Institutional investors hold approximately 32.20% to 41.01% of the company's stock, while insiders own about 12.52%, and public companies and individual investors hold the remaining portion. Major institutional owners include BlackRock, Inc., Janus Henderson Group Plc, and Stifel Financial Corp. Among individual owners, John Childs owns a significant number of shares. Recent insider purchases include CEO Vlad Coric and other executives in November 2025.